請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29324
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李吉仁(Ji-Ren Lee) | |
dc.contributor.author | Ching-Tien Su | en |
dc.contributor.author | 蘇經天 | zh_TW |
dc.date.accessioned | 2021-06-13T01:04:35Z | - |
dc.date.available | 2007-07-26 | |
dc.date.copyright | 2007-07-26 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-22 | |
dc.identifier.citation | 1.Anslinger, P., and Jenk, P., (2004), “Creating Successful Alliances”, Journal of Business Strategy, Vol. 25 (2). pp. 18-22.
2.Barnard, Chester I. (1968), The Functions of the Executive, Cambridge, MA: Harvard University Press. 3.Birch, Steve (2002), Pharmaceutical R&D Outsourcing Strategies: An analysis of market drivers and resistors to 2010, London, UK: Business Insights Limited Publications. 4.Brandenburger, A. M. and Nalebuff, B. J. (1996), Co-opetition, New York, NY: Currency Doubleday. 5.Beverland, M., and Bretherton, P., (2001), “The Uncertain Search for Opportunities: determinants for strategic alliances”, Qualitative Market Research: An International Journal, Vol. 4 (2), pp. 88-99. 6.Burd, Gary, (2000), The Pharmacogenomics Outlook, London, UK: Business Insights Limited Publications. 7.Burrill, G. Steven, (2006), Biotech 2006 Life Sciences: A Changing Prescription, San Francisco, CA: Burrill & Company Publications. 8.Burrill, G. Steven, (2006), The Changing Face of Life Sciences, San Francisco, CA: Burrill & Company Publications. 9.Burrill, G. Steven, (2005), State of Biotechnology Industry: Tends, Concerns and An Outlook for 2005: A Worldwide View, San Francisco, CA: Burrill & Company Publications. 10.Business Insights Ltd, (2001), The Pharmaceutical Mergers and Acquisitions Outlook 2001, London, UK: Business Insights Limited Publications. 11.Chandler, A. D. (1962), Strategy and Structure: Chapters in the History of American Industrial Enterprise, Cambridge, MA: The MIT Press. 12.Coase, R. H. (1937), “The Nature of the Firm”, Economica, 4:386-405. 13.Deutsche Bank, (2005), Global Pharmaceuticals: Pharmaceuticals for Beginner, Munich, Piper: Deutsche Bank Publications. 14.Edelson, S., (2006), “Home Run in Extra Innings”, BioCentury, Vol.14 (17), pp. A2-A4. 15.Ernst & Young, (2006), The Global Biotechnology Report 2006: Beyond Borders, Ernst & Young Publications. 16.Ernst & Young, (2003), The Global Biotechnology Report 2003: Beyond Borders, Ernst & Young Publications. 17.Ernst & Young, (2000), The Economic Contributions of the Biotechnology Industry to the U.S. Economy, Ernst & Young Publications. 18.FDA, (2006), Critical Path Opportunities List, Rockville, MD: FDA Publications. 19.Geller, M., (2003), Biotechnology Handbook: Winter 2002-2003, Toronto, Canada: CIBC World Markets Publications. 20.Hassan, M., Patro, M., Tuckman, H., and Wang, X., (2007) “Do Mergers and Acquisitions Create Shareholder Wealth in the Pharmaceutical Industry?” International Journal of Pharmaceutical and Healthcare Marketing, Vol. 1(1), pp58-78. 21.Moscho, A., Hodits, R.A., Fiedemann, J., and Leiter, M.E., (2000) “Deals that make sense”, Natural Biotechnology, Vol. 18: 719-722. 22.Pfeffer, Jeffrey (1997), New Directions for Organization Theory, New York, NY: Oxford University Press. 23.Penrose, E. T. (1959), The Theory of the Growth of the Firm, New York, NY: John Wiley and Sons. 24.Peterson, Trond (1993), “The Economics of Organization: The principal-Agent Relationship,” Acta Sociologica, 36: 277-293. 25.Piros, E., Selvaraju, R., and Li, A., (2006), Alzheimer’s Disease, New York, NY: Rodman & Renshaw Publicantions. 26.Prudential Equity Group. LLC, (2005), ASCO Themes Suggest A Future of Personalized Medicine, Prudential Equity Group, LLC and Prudential Financial, Inc. 27.Sahoo, Alison (2003), Lifecycle Management Strategies: Maximizing ROI through indication expansion, reformulation and Rx-to-OTC switching, Business Insights Limited Publications. 28.Scott, Richard W. (1992), Organizations: Rational, Natural, and Open Systems, Upper Saddle River, New Jersey: Prentice Hall. 29.Seget, Steven (2006), Biopartnering Strategies: Maximizing returns from biotechnology deal-making, London, UK: Business Insights Limited Publications. 30.Seget, Steven (2006a), Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management, London, UK: Business Insights Limited Publications. 31.Seget, Steven (2006b), Pharmaceutical Strategic Alliances: Maximizing returns from collaborative development and commercialization, London, UK: Business Insights Limited Publications. 32.Seget, Steven (2005), Pharmaceutical Project and Portfolio Management: Effective organization and decision-making for long-term growth, London, UK: Business Insights Limited Publications. 33.Seget, Steven (2002), The Pharmaceutical Licensing Outlook: A strategic guide to effective deal-making and profitable partnerships, London, UK: Business Insights Limited Publications. 34.Smith, Adam (1776), An Inquiry into the Nature and Causes of the Wealth of Nations, New York, NY: Oxford University Press, reissued in 1998. 35.Stach, G., (2006), “Business alliances at Eli Lilly: a successful innovation strategy”, Strategy & Leadership. Vol. 34 (5), pp. 28-33. 36.Walker, Gordon and Weber, David (1984), “A Transaction Cost Approach to Make or Buy Decisions”, Administrative Science Quarterly, 29: 373-391. 37.Williamson, Oliver. E. (1981) “The Economics of Organization: The Transaction Cost Approach”, American Journal of Sociology, 87:548-577. 38.Yang, Xiaokai (2001), Economics: New classical versus Neoclassical Frameworks, New York, NY: Blackwell Publishing. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/29324 | - |
dc.description.abstract | 健康照護產業可以說是最昂貴的服務業。產業中許多次產業,像是醫藥產業與生技產業一直以來的互相依存的競合關係,常常是實務界及學術界共同注意的研究議題。
這篇論文想由生技公司的觀點,尋求一個系統化的方式,來探討其在與大藥廠進行技術交易時,是否能在策略上達到交易價值的極大化,並討論當此價值極大化發生時所應具備的前提條件與情況。 文章中以一家擁有世界級產品潛力的台灣生技公司之新藥產品線為闡述的基礎,並鋪陳可應用至其他領域的產業驅動力來貫穿全文。由於生技公司新藥開發之主要商業模式為授權與被併購,文中亦針對上述價值極大化時於不同商業模式的取捨與決策判斷的條件加以論述。 | zh_TW |
dc.description.abstract | Healthcare industry is possibly the most expensive service industry in the world. To cope with technology changes and innovation challenge, pharmaceutical companies have to engage R&D collaborations with biotechnology companies and develop co-opetition relationship with each other. The smaller biotech companies always have the dilemma to either license-out (to big pharma) or launch the product on their own during collaborative processes.
This thesis illustrates systematically those intrinsic driving forces underlying the co-developing relationship and maps out a strategic scheme for smaller biotech companies to maximize their potential value proposition in dealing with their pharmaceutical counterparts. The schematic model, which focuses on the new perspectives such as intrinsic and extrinsic factors from both biotech and pharmaceutical industries, could be used as an empirical tool in formulating corporate strategies. Finally, a case study using a new drug product pipeline from a Taiwan based biotech company demonstrates a potential best practice deducted from the above scheme. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T01:04:35Z (GMT). No. of bitstreams: 1 ntu-96-P93743025-1.pdf: 4472528 bytes, checksum: 2d0de0310f5ce17bc98495814f88b81b (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | CHAPTER 1 OVERVIEW OF THE THESIS 1
1.1 Introduction 1 1.2 Specific Aims 2 1.3 Structure of the Thesis 2 CHAPTER 2 EMERGING LANDSCAPE OF HEALTHCARE INDUSTRIES 3 2.1 Introduction 3 2.1.1 Healthcare Industry 3 2.1.2 Pharmaceutical Industry 4 2.1.3 Biotechnology Industry 6 2.2 Drug Paradigm Shifts: The Evolving Relationships between Biotechnology and Pharmaceutical Industries 9 2.2.1 From Blockbuster To Personalized Medicine 9 2.2.2 From small molecule based drug to biologics 11 2.2.3 From In-House R&D to Product In-Licensing 12 2.3 Drug Development 13 2.3.1 Pre-clinical Studies: Target Identification and Lead Optimization 14 2.3.2 Clinical Trial 16 2.3.3 Post-Market Management 18 2.4 Strategies to Maximize the Legal and Regulatory Protection 18 2.4.1 Patent Protection 19 2.4.2 Market Exclusivity 20 2.4.3 Cured or Treated – The True Meaning of “Indication” 21 2.4.4 Orphan Drug and Pediatric Usage Status 21 2.4.5 Generic Drugs 22 2.5 Product Lifecycle Management 23 2.5.1 Indication Expansion 24 2.5.2 Reformulation 24 2.5.3 Launch of Derivative Product Line 25 2.5.4 Path to OTC 25 2.6 Pharmaceutical Product Launch Strategies 26 2.7 Summary 29 CHAPTER 3 LITERATURE REVIEW 31 3.1 Introduction 31 3.2 The Trend of Healthcare Industries 31 3.2.1 The co-opetition in pharmaceutical and biotech industry 31 3.3 The Importance of Strategic Alliances and M&A 33 3.3.1 Value Creation through Strategic Alliances in Pharmaceutical Industries 34 3.3.2 Alliance Management Process 34 3.4 Determinants of Strategic Alliances 36 3.4.1 Key Determinants for Strategic Alliances 36 3.4.2 Creating Successfully Alliances 38 3.5 Summary 39 CHAPTER 4 METHODOLOGY 40 4.1 Introduction 40 4.2 A Systematical Approach towards the Match Making Strategies for Biotech Companies 40 4.2.1 Market Dynamics: 41 4.2.2 Pharmaceutical Lifecycle Management: 41 4.2.3 Pharmaceutical Portfolio Management: 42 4.2.4 Biotechnology Project Management: 42 4.2.5 Criteria to maximize potential transaction value in the biotech-pharmaceutical match making process: 43 4.3 Valuation Approaches of International Asset Valuation Standards 43 4.3.1 Market Method 44 4.3.2 Cost Method 44 4.3.3 Income Method (DCF method) 45 4.4 Summary 47 CHAPTER 5 PHARMACEUTICAL PORTFOLIO MANAGEMENT & BIOTECH PROJECT MANAGEMENT 48 5.1 Pharmaceutical Portfolio Management 48 5.1.1 Key Drivers of Pharmaceutical Portfolio Management 48 5.1.2 Pharmaceutical Portfolio Management and Corporate Strategy 50 5.1.3 Growth by Portfolio Management and Project Management 52 5.2 What does Pharmaceutical Portfolio Management Mean to Biotech Companies? 55 5.2.1 Licensing and M&A Strategies by Pharmaceutical Giants through Portfolio Management 57 5.2.2 Pharmaceutical Project Management V.S Biotech Project Management 58 5.2.3 Project Evaluation 60 5.2.4 Project Valuation 60 CHAPTER 6 BIG PHARMA’S PORTFOLIO MANAGEMENT TOWARDS ALZHEIMER’S DISEASE 62 6.1 Market Analysis of Alzheimer’s Disease 62 6.1.1 Alzheimer’s Disease 63 6.1.2 Alzheimer’s Disease Impact 65 6.1.3 Current Solution Providers of Alzheimer’s Disease 66 6.1.4 Potential Entrants Analysis 67 6.1.5 Market Dynamics among Major Players 68 6.2 Meeting Pharma Partner’s Portfolio Management Criteria through Project Management 71 6.2.1 Pfizer’s Portfolio Management 71 6.2.2 Revenue Analysis of Pfizer 72 6.2.2 Risks Caused by Patent Expiry 74 6.2.3 Pfizer’s Current Pipelines 76 6.2.5 Potential Shortfalls Demonstrated by Portfolio Management Analysis 80 CHAPTER 7 RESULTS OF CASE ANALYSIS FOR A TAIWAN-BASE BIOTECH COMPANY’S ALZHEIMER’S DISEASE VACCINE 82 7.1 UBIA, A Local Company with Global Products 82 7.2 UBIA’s Project Management 84 7.3 Evaluation of the Alzheimer’s Disease Product Pipelines 86 7.4 Valuation of the Alzheimer’s Disease Product Pipelines 89 7.5 Match Making Strategy 99 7.6 Summary & Recommendations for the Company 101 CHAPTER 8 CONCLUSIONS 104 8.1 Summary of Findings and Contribution of the Study 104 8.2 Limitations of the study 106 8.3 Recommendations for Future Research 107 | |
dc.language.iso | en | |
dc.title | 生技公司與大藥廠技術交易之價值分析 | zh_TW |
dc.title | Strategic Valuation of Match Making Strategies between Biotech and Pharmaceutical Companies | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃恆獎(Hengchiang Huang),邱奕嘉(Yi-Chia Chiu) | |
dc.subject.keyword | 健康照護,生物科技,製藥,生命週期管理,產品組合管理,專案管理,鑑價, | zh_TW |
dc.subject.keyword | Healthcare,Biotechnology,Pharmaceutical,Product Pipeline,Lifecycle Management,Portfolio Management,Project Management,Valuation, | en |
dc.relation.page | 107 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-24 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 高階公共管理組 | zh_TW |
顯示於系所單位: | 高階公共管理組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 4.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。